Regulation of JNK and p38 MAPK in the immune system: Signal integration, propagation and termination

Cytokine

Volumn 48, Issue 3, 2009, Pages 161-169

  Huang, Gonghua ^a   Shi, Lewis Zhichang ^a   Chi, Hongbo ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Immunity; Kinase; Phosphatase; Receptor; Signaling

Indexed keywords

ANTIINFLAMMATORY AGENT; CYTOKINE; DUAL SPECIFICITY PHOSPHATASE 2; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 5; PHOSPHATASE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UBIQUITIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; AMINO TERMINAL SEQUENCE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CELLULAR IMMUNITY; DISEASE COURSE; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME REGULATION; ENZYME SPECIFICITY; FEEDBACK SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION;

ANIMALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNE SYSTEM; JNK MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 70350028721     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.08.002     Document Type: Review

References (111)

1. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 (2006) 783-801
2. Joffre O., Nolte M.A., Sporri R., and Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 227 (2009) 234-247
3. O'Neill L.A. When signaling pathways collide: positive and negative regulation of toll-like receptor signal transduction. Immunity 29 (2008) 12-20
4. Ivashkiv L.B. A signal-switch hypothesis for cross-regulation of cytokine and TLR signalling pathways. Nat Rev Immunol 8 (2008) 816-822
5. Hu X., Chen J., Wang L., and Ivashkiv L.B. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol 82 (2007) 237-243
6. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81 (2001) 807-869
7. Symons A., Beinke S., and Ley S.C. MAP kinase kinase kinases and innate immunity. Trends Immunol. 27 (2006) 40-48
8. Winter-Vann A.M., and Johnson G.L. Integrated activation of MAP3Ks balances cell fate in response to stress. J Cell Biochem 102 (2007) 848-858
9. Ashwell J.D. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol. 6 (2006) 532-540
10. Keyse S.M. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27 (2008) 253-261
11. Owens D.M., and Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26 (2007) 3203-3213
12. Liu Y., Shepherd E.G., and Nelin L.D. MAPK phosphatases-regulating the immune response. Nat Rev Immunol 7 (2007) 202-212
13. Su B., Jacinto E., Hibi M., Kallunki T., Karin M., and Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lymphocytes. Cell 77 (1994) 727-736
14. Dong C., Davis R.J., and Flavell R.A. MAP kinases in immune response. Annu Rev Immunol 20 (2002) 55-72
15. Rincon M., and Davis R.J. Regulation of the immune response by stress-activated protein kinases. Immunol Rev 228 (2009) 212-224
16. Bain J., McLauchlan H., Elliott M., and Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 371 (2003) 199-204
17. Bain J., Plater L., Elliott M., Shpiro N., Hastie J., McLauchlan H., et al. The selectivity of protein kinase inhibitors; a further update. Biochem J 408 (2007) 297-315
18. Zhuang Z.H., Zhou Y., Yu M.C., Silverman N., and Ge B.X. Regulation of Drosophila p38 activation by specific MAP2 kinase and MAP3 kinase in response to different stimuli. Cell Signal 18 (2006) 441-448
19. Adhikari A., Xu M., and Chen Z.J. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 26 (2007) 3214-3226
20. Yamaguchi K., Shirakabe K., Shibuya H., Irie K., Oishi I., Ueno N., et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 270 (1995) 2008-2011
21. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., and Matsumoto K. The kinase TAK1 can activate the NIK-I κB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398 (1999) 252-256
22. Takaesu G., Surabhi R.M., Park K.J., Ninomiya-Tsuji J., Matsumoto K., and Gaynor R.B. TAK1 is critical for IκB kinase-mediated activation of the NF-κB pathway. J Mol Biol 326 (2003) 105-115
23. Vidal S., Khush R.S., Leulier F., Tzou P., Nakamura M., and Lemaitre B. Mutations in the Drosophila dTAK1 gene reveal a conserved function for MAPKKKs in the control of rel/NF-κB-dependent innate immune responses. Genes Dev 15 (2001) 1900-1912
24. Silverman N., Zhou R., Erlich R.L., Hunter M., Bernstein E., Schneider D., et al. Immune activation of NF-κB and JNK requires Drosophila TAK1. J Biol Chem 278 (2003) 48928-48934
25. Jadrich J.L., O'Connor M.B., and Coucouvanis E. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development 133 (2006) 1529-1541
26. Shim J.H., Xiao C., Paschal A.E., Bailey S.T., Rao P., Hayden M.S., et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev. 19 (2005) 2668-2681
27. Sato S., Sanjo H., Takeda K., Ninomiya-Tsuji J., Yamamoto M., Kawai T., et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 6 (2005) 1087-1095
28. Hasegawa M., Fujimoto Y., Lucas P.C., Nakano H., Fukase K., Nunez G., et al. A critical role of RICK/RIP2 polyubiquitination in Nod-induced NF-κB activation. Embo J 27 (2008) 373-383
29. Kim J.Y., Omori E., Matsumoto K., Nunez G., and Ninomiya-Tsuji J. TAK1 is a central mediator of NOD2 signaling in epidermal cells. J Biol Chem 283 (2008) 137-144
30. Qin J., Yao J., Cui G., Xiao H., Kim T.W., Fraczek J., et al. TLR8-mediated NF-κB and JNK activation are TAK1-independent and MEKK3-dependent. J Biol Chem 281 (2006) 21013-21021
31. Sun L., Deng L., Ea C.K., Xia Z.P., and Chen Z.J. The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes. Mol Cell 14 (2004) 289-301
32. Wan Y.Y., Chi H., Xie M., Schneider M.D., and Flavell R.A. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 7 (2006) 851-858
33. Sato S., Sanjo H., Tsujimura T., Ninomiya-Tsuji J., Yamamoto M., Kawai T., et al. TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int Immunol 18 (2006) 1405-1411
34. Liu H.H., Xie M., Schneider M.D., and Chen Z.J. Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci USA 103 (2006) 11677-11682
35. Shinohara H., Yasuda T., Aiba Y., Sanjo H., Hamadate M., Watarai H., et al. PKC beta regulates BCR-mediated IKK activation by facilitating the interaction between TAK1 and CARMA1. J Exp Med 202 (2005) 1423-1431
36. Schuman J., Chen Y., Podd A., Yu M., Liu H.H., Wen R., et al. A critical role of TAK1 in B cell receptor-mediated NF-κB activation. Blood 113 (2009) 4566-4574
37. Bhoj V.G., and Chen Z.J. Ubiquitylation in innate and adaptive immunity. Nature 458 (2009) 430-437
38. Ea C.K., Deng L., Xia Z.P., Pineda G., and Chen Z.J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol Cell 22 (2006) 245-257
39. Kanayama A., Seth R.B., Sun L., Ea C.K., Hong M., Shaito A., et al. TAB2 and TAB3 activate the NF-κB pathway through binding to polyubiquitin chains. Mol Cell 15 (2004) 535-548
40. Wu C.J., Conze D.B., Li T., Srinivasula S.M., and Ashwell J.D. Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation [corrected]. Nat Cell Biol 8 (2006) 398-406
41. Conze D.B., Wu C.J., Thomas J.A., Landstrom A., and Ashwell J.D. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-κB activation. Mol Cell Biol 28 (2008) 3538-3547
42. Wu C.J., and Ashwell J.D. NEMO recognition of ubiquitinated Bcl10 is required for T cell receptor-mediated NF-κB activation. Proc Natl Acad Sci USA 105 (2008) 3023-3028
43. King C.G., Kobayashi T., Cejas P.J., Kim T., Yoon K., Kim G.K., et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med 12 (2006) 1088-1092
44. Shambharkar P.B., Blonska M., Pappu B.P., Li H., You Y., Sakurai H., et al. Phosphorylation and ubiquitination of the IκB kinase complex by two distinct signaling pathways. Embo J 26 (2007) 1794-1805
45. Blonska M., Pappu B.P., Matsumoto R., Li H., Su B., Wang D., et al. The CARMA1-Bcl10 signaling complex selectively regulates JNK2 kinase in the T cell receptor-signaling pathway. Immunity 26 (2007) 55-66
46. Xia Y., Makris C., Su B., Li E., Yang J., Nemerow G.R., et al. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci USA 97 (2000) 5243-5248
47. Yujiri T., Ware M., Widmann C., Oyer R., Russell D., Chan E., et al. MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-κB activation. Proc Natl Acad Sci USA 97 (2000) 7272-7277
48. Yujiri T., Sather S., Fanger G.R., and Johnson G.L. Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption. Science 282 (1998) 1911-1914
49. Gao M., Labuda T., Xia Y., Gallagher E., Fang D., Liu Y.C., et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 306 (2004) 271-275
50. Venuprasad K., Elly C., Gao M., Salek-Ardakani S., Harada Y., Luo J.L., et al. Convergence of Itch-induced ubiquitination with MEKK1-JNK signaling in Th2 tolerance and airway inflammation. J Clin Invest. 116 (2006) 1117-1126
51. Gallagher E., Enzler T., Matsuzawa A., Anzelon-Mills A., Otero D., Holzer R., et al. Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production. Nat Immunol 8 (2007) 57-63
52. Matsuzawa A., Tseng P.H., Vallabhapurapu S., Luo J.L., Zhang W., Wang H., et al. Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex. Science 321 (2008) 663-668
53. Gerwins P., Blank J.L., and Johnson G.L. Cloning of a novel mitogen-activated protein kinase kinase kinase, MEKK4, that selectively regulates the c-Jun amino terminal kinase pathway. J Biol Chem 272 (1997) 8288-8295
54. Takekawa M., Posas F., and Saito H. A human homolog of the yeast Ssk2/Ssk22 MAP kinase kinase kinases, MTK1, mediates stress-induced activation of the p38 and JNK pathways. Embo J 16 (1997) 4973-4982
55. Chi H., Sarkisian M.R., Rakic P., and Flavell R.A. Loss of mitogen-activated protein kinase kinase kinase 4 (MEKK4) results in enhanced apoptosis and defective neural tube development. Proc Natl Acad Sci USA 102 (2005) 3846-3851
56. Abell A.N., Rivera-Perez J.A., Cuevas B.D., Uhlik M.T., Sather S., Johnson N.L., et al. Ablation of MEKK4 kinase activity causes neurulation and skeletal patterning defects in the mouse embryo. Mol Cell Biol 25 (2005) 8948-8959
57. Chi H., Lu B., Takekawa M., Davis R.J., and Flavell R.A. GADD45beta/GADD45gamma and MEKK4 comprise a genetic pathway mediating STAT4-independent IFNgamma production in T cells. EMBO J 23 (2004) 1576-1586
58. Takekawa M., and Saito H. A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 95 (1998) 521-530
59. Wang X., Gorospe M., and Holbrook N.J. Gadd45 is not required for activation of c-Jun N-terminal kinase or p38 during acute stress. J Biol Chem 274 (1999) 29599-29602
60. Shaulian E., and Karin M. Stress-induced JNK activation is independent of Gadd45 induction. J Biol Chem 274 (1999) 29595-29598
61. Lu B., Yu H., Chow C., Li B., Zheng W., Davis R.J., et al. GADD45gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells. Immunity 14 (2001) 583-590
62. Lu B., Ferrandino A.F., and Flavell R.A. Gadd45[beta] is important for perpetuating cognate and inflammatory signals in T cells. Nat Immunol 5 (2004) 38-44
63. Miyake Z., Takekawa M., Ge Q., and Saito H. Activation of MTK1/MEKK4 by GADD45 through induced N-C dissociation and dimerization-mediated trans autophosphorylation of the MTK1 kinase domain. Mol Cell Biol 27 (2007) 2765-2776
64. Mita H., Tsutsui J., Takekawa M., Witten E.A., and Saito H. Regulation of MTK1/MEKK4 kinase activity by its N-terminal autoinhibitory domain and GADD45 binding. Mol Cell Biol 22 (2002) 4544-4555
65. Blank J.L., Gerwins P., Elliott E.M., Sather S., and Johnson G.L. Molecular cloning of mitogen-activated protein/ERK kinase kinases (MEKK) 2 and 3. v. J Biol Chem 271 (1996) 5361-5368
66. Yang J., Boerm M., McCarty M., Bucana C., Fidler I.J., Zhuang Y., et al. Mekk3 is essential for early embryonic cardiovascular development. Nat Genet 24 (2000) 309-313
67. Huang Q., Yang J., Lin Y., Walker C., Cheng J., Liu Z.G., et al. Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol 5 (2004) 98-103
68. Yang J., Lin Y., Guo Z., Cheng J., Huang J., Deng L., et al. The essential role of MEKK3 in TNF-induced NF-κB activation. Nat Immunol 2 (2001) 620-624
69. Wang X., Chang X., Facchinetti V., Zhuang Y., and Su B. MEKK3 is essential for lymphopenia-induced T cell proliferation and survival. J Immunol 182 (2009) 3597-3608
70. Shinohara H., Yamasaki S., Maeda S., Saito T., and Kurosaki T. Regulation of NF-κB-dependent T cell activation and development by MEKK3. Int Immunol 21 (2009) 393-401
71. Zhang D., Facchinetti V., Wang X., Huang Q., Qin J., and Su B. Identification of MEKK2/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways. Embo J 25 (2006) 97-107
72. Matsuzawa A., Saegusa K., Noguchi T., Sadamitsu C., Nishitoh H., Nagai S., et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol 6 (2005) 587-592
73. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K., Takeda K., et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep 2 (2001) 222-228
74. Guo Z., Clydesdale G., Cheng J., Kim K., Gan L., McConkey D.J., et al. Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol Cell Biol 22 (2002) 5761-5768
75. Hauge C., and Frodin M. RSK and MSK in MAP kinase signalling. J Cell Sci 119 (2006) 3021-3023
76. Zaru R., Ronkina N., Gaestel M., Arthur J.S., and Watts C. The MAPK-activated kinase Rsk controls an acute Toll-like receptor signaling response in dendritic cells and is activated through two distinct pathways. Nat Immunol 8 (2007) 1227-1235
77. Wiggin G.R., Soloaga A., Foster J.M., Murray-Tait V., Cohen P., and Arthur J.S. MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 22 (2002) 2871-2881
78. Soloaga A., Thomson S., Wiggin G.R., Rampersaud N., Dyson M.H., Hazzalin C.A., et al. MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. Embo J 22 (2003) 2788-2797
79. Ananieva O., Darragh J., Johansen C., Carr J.M., McIlrath J., Park J.M., et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 9 (2008) 1028-1036
80. Kim C., Sano Y., Todorova K., Carlson B.A., Arpa L., Celada A., et al. The kinase p38 alpha serves cell type-specific inflammatory functions in skin injury and coordinates pro- and anti-inflammatory gene expression. Nat Immunol 9 (2008) 1019-1027
81. Park J.M., Greten F.R., Wong A., Westrick R.J., Arthur J.S., Otsu K., et al. Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis-CREB and NF-κB as key regulators. Immunity 23 (2005) 319-329
82. Saccani S., Pantano S., and Natoli G. P38-Dependent marking of inflammatory genes for increased NF-κB recruitment. Nat Immunol 3 (2002) 69-75
83. Musti A.M., Treier M., and Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 275 (1997) 400-402
84. Fuchs S.Y., Dolan L., Davis R.J., and Ronai Z. Phosphorylation-dependent targeting of c-Jun ubiquitination by Jun N-kinase. Oncogene 13 (1996) 1531-1535
85. Nateri A.S., Riera-Sans L., Da Costa C., and Behrens A. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303 (2004) 1374-1378
86. Laine A, Ronai Z. Ubiquitin chains in the ladder of MAPK signaling. Sci STKE 2005;2005: re5.
87. Dickinson R.J., and Keyse S.M. Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119 (2006) 4607-4615
88. Franklin C.C., and Kraft A.S. Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 Cells. J Biol Chem 272 (1997) 16917-16923
89. Chi H., Barry S.P., Roth R.J., Wu J.J., Jones E.A., Bennett A.M., et al. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci USA 103 (2006) 2274-2279
90. Hammer M., Mages J., Dietrich H., Servatius A., Howells N., Cato A.C., et al. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 203 (2006) 15-20
91. Zhao Q., Wang X., Nelin L.D., Yao Y., Matta R., Manson M.E., et al. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 203 (2006) 131-140
92. Salojin K.V., Owusu I.B., Millerchip K.A., Potter M., Platt K.A., and Oravecz T. Essential role of MAPK phosphatase-1 in the negative control of innate immune responses. J Immunol 176 (2006) 1899-1907
93. Chen P., Li J., Barnes J., Kokkonen G.C., Lee J.C., and Liu Y. Restraint of proinflammatory cytokine biosynthesis by mitogen-activated protein kinase phosphatase-1 in lipopolysaccharide-stimulated macrophages. J Immunol 169 (2002) 6408-6416
94. Zhao Q., Shepherd E.G., Manson M.E., Nelin L.D., Sorokin A., and Liu Y. The role of mitogen-activated protein kinase phosphatase-1 in the response of alveolar macrophages to lipopolysaccharide: attenuation of proinflammatory cytokine biosynthesis via feedback control of p38. J Biol Chem 280 (2005) 8101-8108
95. Hu J.H., Chen T., Zhuang Z.H., Kong L., Yu M.C., Liu Y., et al. Feedback control of MKP-1 expression by p38. Cell Signal 19 (2007) 393-400
96. Abraham S.M., Lawrence T., Kleiman A., Warden P., Medghalchi M., Tuckermann J., et al. Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1. J Exp Med 203 (2006) 1883-1889
97. Chi H., Bennett A.M., and Flavell R.A. Mitogen-activated protein kinase phosphatase-1 (MKP-1): a critical regulator of innate immune responses. J Organ Dysfunct 3 (2007) 72-81
98. Brondello J.M., Pouysségur J., and McKenzie F.R. Reduced MAP kinase phosphatase-1 degradation after p42/p44MAPK-dependent phosphorylation. Science 286 (1999) 2514-2517
99. Lin Y.W., Chuang S.M., and Yang J.L. ERK1/2 achieves sustained activation by stimulating MAPK phosphatase-1 degradation via the ubiquitin-proteasome pathway. J Biol Chem 278 (2003) 21534-21541
100. Lin Y.W., and Yang J.L. Cooperation of ERK and SCFSkp2 for MKP-1 destruction provides a positive feedback regulation of proliferating signaling. J Biol Chem 281 (2006) 915-926
101. Kamata H., Honda S., Maeda S., Chang L., Hirata H., and Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120 (2005) 649-661
102. Chi H., and Flavell R.A. Acetylation of MKP-1 and the control of inflammation. Sci Signal 1 (2008) pe44
103. Cao W., Bao C., Padalko E., and Lowenstein C.J. Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med 205 (2008) 1491-1503
104. Zhang Y., Blattman J.N., Kennedy N.J., Duong J., Nguyen T., Wang Y., et al. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 430 (2004) 793-797
105. Jeffrey K.L., Brummer T., Rolph M.S., Liu S.M., Callejas N.A., Grumont R.J., et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 7 (2006) 274-283
106. Shen Y.H., Godlewski J., Zhu J., Sathyanarayana P., Leaner V., Birrer M.J., et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem 278 (2003) 26715-26721
107. Zhang H., Shi X., Hampong M., Blanis L., and Pelech S. Stress-induced inhibition of ERK1 and ERK2 by direct interaction with p38 MAP kinase. J Biol Chem 276 (2001) 6905-6908
108. Kumar S., Boehm J., and Lee J.C. P38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2 (2003) 717-726
109. Manning A.M., and Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat Rev Drug Discov 2 (2003) 554-565
110. Jeffrey K.L., Camps M., Rommel C., and Mackay C.R. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6 (2007) 391-403
111. Dambach D.M. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 5 (2005) 929-939